Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Wurtz

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Journal of Medicinal Chemistry|May 15, 2020
Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart FailureYoshikazu Asahina, Nicholas R Wurtz, Kazuto Arakawa, et al.
ACS Pharmacology & Translational Science|October 21, 2022
Molecular Mechanisms of Desensitization Underlying the Differential Effects of Formyl Peptide Receptor 2 Agonists on Cardiac Structure-Function Post Myocardial InfarctionJohn Lupisella, Stéphane St-Onge, Marilyn Carrier, et al.
EMBO Molecular Medicine|April 3, 2025
Formyl-peptide receptor type 2 activation mitigates heart and lung damage in inflammatory arthritisAndreas Margraf, Jianmin Chen, Marilena Christoforou, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa InhibitorsXiaojun Zhang, Wen Jiang, Swanee Jacutin-Porte, et al.
ACS Medicinal Chemistry Letters|September 18, 2024
Discovery and Optimization of Aryl Piperidinone Ureas as Selective Formyl Peptide Receptor 2 AgonistsNicholas R Wurtz, Pravin S Shirude, Daniel L Cheney, et al.
Medchemcomm|August 16, 2018
Triazolopyrimidines identified as reversible myeloperoxidase inhibitorsFranck Duclos, Lynn M Abell, David G Harden, et al.
JACC. Basic to Translational Science|January 8, 2020
Preservation of Post-Infarction Cardiac Structure and Function via Long-Term Oral Formyl Peptide Receptor Agonist TreatmentRicardo A García, Bruce R Ito, John A Lupisella, et al.
JACC. Basic to Translational Science|September 1, 2021
Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial InfarctionRicardo A García, John A Lupisella, Bruce R Ito, et al.
Journal of Medicinal Chemistry|February 17, 2026
From Lead to Clinical Candidate: Discovery of BMS-986331 as a Potent and Selective <i>N</i>-Formyl Peptide Receptor 2 AgonistPravin S Shirude, Daniel Cheney, Amit K Chattopadhyay, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Journal of Medicinal Chemistry|May 15, 2020
Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart FailureYoshikazu Asahina, Nicholas R Wurtz, Kazuto Arakawa, et al.
ACS Pharmacology & Translational Science|October 21, 2022
Molecular Mechanisms of Desensitization Underlying the Differential Effects of Formyl Peptide Receptor 2 Agonists on Cardiac Structure-Function Post Myocardial InfarctionJohn Lupisella, Stéphane St-Onge, Marilyn Carrier, et al.
EMBO Molecular Medicine|April 3, 2025
Formyl-peptide receptor type 2 activation mitigates heart and lung damage in inflammatory arthritisAndreas Margraf, Jianmin Chen, Marilena Christoforou, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa InhibitorsXiaojun Zhang, Wen Jiang, Swanee Jacutin-Porte, et al.
ACS Medicinal Chemistry Letters|September 18, 2024
Discovery and Optimization of Aryl Piperidinone Ureas as Selective Formyl Peptide Receptor 2 AgonistsNicholas R Wurtz, Pravin S Shirude, Daniel L Cheney, et al.
Medchemcomm|August 16, 2018
Triazolopyrimidines identified as reversible myeloperoxidase inhibitorsFranck Duclos, Lynn M Abell, David G Harden, et al.
JACC. Basic to Translational Science|January 8, 2020
Preservation of Post-Infarction Cardiac Structure and Function via Long-Term Oral Formyl Peptide Receptor Agonist TreatmentRicardo A García, Bruce R Ito, John A Lupisella, et al.
JACC. Basic to Translational Science|September 1, 2021
Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial InfarctionRicardo A García, John A Lupisella, Bruce R Ito, et al.
Journal of Medicinal Chemistry|February 17, 2026
From Lead to Clinical Candidate: Discovery of BMS-986331 as a Potent and Selective <i>N</i>-Formyl Peptide Receptor 2 AgonistPravin S Shirude, Daniel Cheney, Amit K Chattopadhyay, et al.
Pageof 6